BioSpace News Archive

Drug Development

Telios Pharma Announces Successful Phase 2 Results for TL-925, a Novel Treatment for Dry Eye Disease

Telios Pharma, Inc. today announced topline results from its Phase 2 study assessing TL-925, a first-in-class topical Bruton’s tyrosine kinase (BTK) inhibitor for individuals with moderate to severe dry eye disease (DED).

March 6, 2024
·
4 min read
Business

Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers

Gilead Sciences, Inc. (Nasdaq:GILD) and Merus N.V. (Nasdaq:MRUS) today announced a research collaboration, option and license agreement to discover novel dual tumor-associated antigens (TAA) targeting trispecific antibodies.

March 6, 2024
·
9 min read
Hummingbird Diagnostics Announces Publication Evaluating miR-Blood’s Small RNA Expression Dataset Capabilities in Nature’s Scientific Data

Hummingbird Diagnostics GmbH today announced a publication in Scientific Data, a peer-reviewed, open-access journal launched by Nature.

March 6, 2024
·
2 min read
BioMidwest

Innoveren Scientific Announces 510(k) Submission for SkinDisc(TM) Lite

Innoveren Scientific Inc. (OTCQB:IVRN) (“Innoveren” or the “Company”), a life science company focused on becoming a leading biotech incubator, announced today that it has submitted a 510(k) premarket filing to the U.S. Federal Food and Drug Administration (FDA) for its SkinDiscTM Lite product.

March 6, 2024
·
3 min read
Drug Development

Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma

Bausch Health Companies Inc. today announced that it is supporting a Phase 2 investigator-initiated study (IIS) of RELISTOR (methylnaltrexone bromide: MNTX) in patients with resectable head and neck squamous cell carcinoma.

March 6, 2024
·
7 min read
Lone Star Bio

Sporos BioDiscovery to Present Preclinical Findings on SPR1, a Next-Generation TEAD Inhibitor, at the American Association for Cancer Research (AACR) Annual Meeting 2024

Sporos BioDiscovery, Inc. today announced that it will present two posters highlighting preclinical data from the company’s novel TEAD1 / TEAD4 isoform selective inhibitor, SPR1, at the American Association for Cancer Research (AACR) Annual Meeting 2024.

March 6, 2024
·
2 min read
Business

Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell

Hepion Pharmaceuticals, Inc. today announced the appointment of Michael Purcell to the Company’s Board of Directors, effective March 5, 2024.

March 6, 2024
·
3 min read
Biotech Bay

New Pacific Research Institute Brief: Regulatory Roadblocks Hinder Development of New COVID-19 Treatments for the Immunocompromised

The current federal regulatory process to develop monoclonal antibodies to treat mutating strains of COVID-19 imposes unnecessary hurdles that hinder the creation and approval of effective treatments for the immunocompromised, finds a new brief released by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute.

March 6, 2024
·
2 min read
Genetown

Bioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonist

BIOXYTRAN, INC. announced the preprint in ResearchGate entitled “Association of Rapid Shingles Lesion Clearance and Regression of Herpes Zoster Neuralgia in Case Study Using Topical Galectin-3 Antagonism” showed a time lapsed clearance of the shingles lesions using a topical Galectin-3 antagonist.

March 6, 2024
·
3 min read
Pharm Country

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

Cyclacel Pharmaceuticals, Inc. announced that it received £2.3 million as a research & development tax credit from HMRC, the tax agency of the United Kingdom government.

March 6, 2024
·
1 min read